Understanding the symptoms children with cancer experience is a valuable asset for medical professionals. Prevalence, severity, and distress of symptoms can vary throughout the course of the illness—during diagnosis, treatment, and hospitalization (Yeh et al., 2008). Although mortality rates for childhood cancer have declined by more than 50% since 1975, cancer is one of the leading causes of death in children, second only to accidents (American Cancer Society, 2011). Higher survival rates have been achieved through the use of improved treatments, aggressive chemotherapy, medication, and increased patient participation in clinical trials (American Cancer Society, 2011; Linder, 2005). However, the severity and distress of symptoms experienced by children as they undergo life-sustaining treatments continue to persist.

Since the early 2000s, an increase has occurred in the number of studies documenting symptom prevalence in children. Pediatric symptom research provides clinicians with the understanding of how growth, development, metabolism, and other physiologic factors affect a child’s experience with cancer and treatment (Baggott, Dodd, Kennedy, Marina, & Miaskowski, 2009). Although several adult-focused studies on symptoms have been conducted, their findings cannot be generalized to the pediatric population because of physiologic differences between children and adults (Baggott et al., 2009). Adult-focused research provided direction for pediatric research in the areas of data collection and organization of symptoms, specifically through the use of multidimensional scales and the concept of symptom clusters (Collins et al., 2000; Hockenberry et al., 2010).

Current research has shown that symptom severity can potentially delay treatment, its effectiveness, and recovery. However, the very symptoms that potentially had a negative effect on long-term outcomes often were overlooked for the sake of disease-curing treatment interventions (Hockenberry & Hooke, 2007; Yeh et al., 2008). Acute and delayed side effects were present throughout the course of cancer diagnosis and treatment or during end-of-life...